HCPLive has published a recap rounding up the top five psoriasis headlines from the EADV 2026 congress, consolidating the congress's most clinically relevant developments into a single briefing for dermatology practitioners.

The roundup format has become a fixture of major congress coverage. EADV draws thousands of dermatologists annually, and psoriasis consistently dominates the scientific program — from IL-17 and IL-23 inhibitor data to real-world registry findings and treatment-sequencing debates. HCPLive's editors selected five stories from that program as the headlines most worth a clinician's time.

What does this change for psoriasis practice?

On its own, the recap is a navigation tool, not a new dataset. Its value is triage: it tells busy clinicians which of the hundreds of EADV 2026 psoriasis presentations carried the most practice-moving weight, and where to spend their reading time first. Congress recaps of this kind typically flag late-breaking trial readouts, regulatory-adjacent data, and shifts in how biologics and oral agents are positioned against each other.

For psoriasis specifically, the headline categories that recur at every EADV include:

• Long-term efficacy and safety extensions for approved biologics
• Head-to-head comparisons between mechanism classes
• Real-world persistence and discontinuation data
• Candidate therapies advancing toward regulatory submission
• Management strategies for special populations and difficult-to-treat sites

HCPLive's five selections sit somewhere within that frame, and readers should treat the recap as a curated index into the full congress record rather than a substitute for it.

Why congress recaps matter

The volume problem at EADV is real. A single congress can feature hundreds of psoriasis abstracts across oral and poster sessions, and no clinician can review them all. Editorial curation — five headlines, ranked and summarized — compresses that volume into something actionable between patient visits.

The recap also serves a second function: it signals which lines of psoriasis research the editorial layer of the specialty considers momentum-bearing heading into the next publication and approval cycle. What appears in a top-five list at EADV 2026 often foreshadows the data that will populate late-phase readouts and label discussions over the following year.

Derm Field will follow the individual stories behind these headlines as the full EADV 2026 data are published in the peer-reviewed literature.